On 11 January 2016, orphan designation (EU/3/15/1603) was granted by the European Commission to Medpace Germany GmbH, Germany, for live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin (also known as CRS-207) for the treatment of pancreatic cancer.
The sponsorship was transferred to Aduro Biotech Holdings, Europe B.V., The Netherlands, in April 2016.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.
EU/3/15/1603: Public summary of opinion on orphan designation: Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin for the treatment of pancreatic cancer (PDF/204.97 KB)
First published: 05/02/2016
Last updated: 05/02/2016
Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin
|Disease / condition||
Treatment of pancreatic cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
Pivot Park RX 1101
5349 AC Oss
Tel. +31 8 80 12 14 00
Fax +31 2 07 11 81 40
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;